Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
NovaBay anounces details of dermatology program
Emeryville, Calif. - NovaBay Parmaceuticals announces it has successfully developed several formulations of Agonocide compounds for use in dermatology.
Emeryville, Calif.
- NovaBay Parmaceuticals announces it has successfully developed several formulations of Agonocide compounds for use in dermatology, according to iStockAnalysis.com.
One formulations, AgaDerm, delivers an Aganocide compound effectively when applied on the surface of the skin, and furthered penetration into hair follicles to treat fungal infections.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
